NEWTOWN | Jotup

DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating Claims on Behalf of Customers Whose Personal Data May Have Been Compromised by the Greylock McKinnon Associates, Inc. Data Breach

Retrieved on:

Tuesday, April 9, 2024

Name, Social Security, Medicare, Privacy, Social, HERE, LLP, Private investigator

NEWTOWN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating claims regarding data privacy violations by Greylock McKinnon Associates, Inc. Greylock McKinnon learned of suspicious activity on or about May 30, 2023.

Key Points:

NEWTOWN, Pa., April 09, 2024 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP, a national class action law firm, is investigating claims regarding data privacy violations by Greylock McKinnon Associates, Inc. Greylock McKinnon learned of suspicious activity on or about May 30, 2023.
On or about May 30, 2023, Greylock McKinnon detected unusual activity on its internal network and took action to address the situation, including consulting with third-party cybersecurity experts about the incident.
How can I protect my personal data?
Edelson Lechtzin LLP is investigating bringing a class action lawsuit to seek legal remedies on behalf of customers who may have had their sensitive personal and patient data compromised by the Greylock McKinnon data breach.

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Personal Data May Have Been Compromised By The City of Hope Data Breach

Retrieved on:

Friday, April 5, 2024

Social Security, Privacy, City, Social, Computer, HERE, LLP

NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by City of Hope, a cancer hospital and research center.

Key Points:

NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by City of Hope, a cancer hospital and research center.
City of Hope learned of suspicious activity on or about October 13, 2023.
On or about October 13, 2023, City of Hope detected suspicious activity on its computer systems and took immediate action to contain it.
Edelson Lechtzin LLP is investigating bringing a class action lawsuit to seek legal remedies on behalf of customers who may have had their sensitive personal and patient data compromised by the City of Hope data breach.

DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Customers Whose Personal Data May Have Been Compromised By The On Q Financial, LLC Data Breach

Retrieved on:

Friday, April 5, 2024

Social Security, Privacy, Social, ConnectWise Control, HERE, LLP, Software, Cryptocurrency

NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by On Q Financial, LLC.

Key Points:

NEWTOWN, Pa., April 05, 2024 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating claims regarding data privacy violations by On Q Financial, LLC.
On Q Financial learned of suspicious activity on or about February 20, 2024.
On or about February 20, 2024, On Q Financial received a notification from a third-party software vendor regarding a vulnerability in its product, ScreenConnect, which On Q Financial used for remote computer access.
Edelson Lechtzin LLP is investigating bringing a class action lawsuit to seek legal remedies on behalf of customers who may have had their sensitive personal and patient data compromised by the On Q Financial data breach.

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™

Retrieved on:

Wednesday, April 3, 2024

Diagnosis, Department of Defence, Service-Disabled Veteran-Owned Small Business, Gait, USMC, RET, SBA, Walking, Patient, HSDT, Quality of life, Small business, Pons, Pharmaceutical industry

NEWTOWN, Pa., April 03, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced it has partnered with Lovell Government Services (“Lovell”), an SBA-certified Service Disabled Veteran Owned Small Business (“SDVOSB”), to make the Company’s Portable Neuromodulation Stimulator (“PoNS®”) device available to federal healthcare systems. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.

Key Points:

In a study of real-world results, after 14 weeks of PoNS Therapy, 100% of MS patients experienced a clinically meaningful improvement in gait.
Veterans have given their best to our country and should have access to the most innovative and effective resources available.
“Recently, Helius highlighted the real-life story of Kevin Byrne, a retired U.S. veteran who’s been suffering from MS since 1999.
While clinical results have demonstrated the effectiveness of PoNS Therapy, it’s firsthand accounts like Captain Byrne’s that are the most gratifying,” concluded Andreeff.

Traws Pharma Announces New Employee Inducement Grants

Retrieved on:

Tuesday, April 2, 2024

Employment, Acquisition, Therapy

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).

Key Points:

NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
On April 1, 2024, Traws granted restricted stock equity awards to Werner Cautreels, Iain Dukes, Nikolay Savchuk, C. David Pauza and Robert Redfield, as an inducement for each of them to accept employment, which equity awards relate to, 200,000, 67,500, 67,500, 97,500 and 97,500 shares of Traws common stock.
One-quarter (1/4) of the shares subject to each restricted stock equity award will vest on each of the first four anniversaries of the grant date, conditioned upon each employee’s continued employment on the vesting date(s).
The inducement grants were approved by Traws’ Compensation Committee of the Board of Directors, as required by NASDAQ Rule 5635(c)(4), and were granted as a material inducement to employment in accordance with NASDAQ Rule 5635(c)(4).

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on:

Tuesday, April 2, 2024

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points:

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
Topline data are expected H2 2024
Phase 2 study planned to be initiated in H2 2024.

Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

Thursday, March 28, 2024

Research, HCPCS, Gait, Patient, Operating cost, Stroke, Sale, Acquisition, HSDT, Andreyev, Social services, ATM, Pons, Medicare, FDA, CMS, PTAP, Food, Video game

NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced results for the quarter and full year ended December 31, 2023.

Key Points:

Gross profit for the fourth quarter of 2023 was $44 thousand, compared to gross profit of $132 thousand in the fourth quarter of 2022.
Operating loss for the fourth quarter of 2023 decreased to a loss of $2.2 million, compared to an operating loss of $2.7 million in the fourth quarter of 2022.
Net loss was $1.0 million for the fourth quarter of 2023, compared to a net loss of $4.9 million in the fourth quarter of 2022.
The basic and diluted net loss per share for the fourth quarter 2023 was $1.47, compared to net loss per share of $8.66 in the fourth quarter 2022.

Unity Consortium Marks Adolescent Immunization Action Week (AIAW) with activities to help Parents and Adolescents get up to date on Recommended Vaccines

Retrieved on:

Thursday, March 28, 2024

AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.

Key Points:

AIAW is a national movement aimed at parents, adolescents and healthcare providers to ensure adolescents are up to date on well visits and recommended vaccines.
Across the nation, organizations interested in the health of adolescents are participating in AIAW to help protect adolescents from vaccine-preventable illnesses.
To address these challenges, Unity wants parents to help adolescents and young adults stay healthy by Staying on TASK with vaccines.
As AIAW kicks off, Unity offers activities and resources to support Adolescent Immunization Action Week efforts, including:
A graphic and video animation of Staying on TASK.

EVVTY INVESTOR ALERT: Edelson Lechtzin LLP Reminds Evolution AB (publ) (OTC: EVVTY) Shareholders About the March 25 Deadline to Move for Lead Plaintiff in the Pending Securities Fraud Class Action

Retrieved on:

Tuesday, March 19, 2024

Growth, District court, LLP, Evolution, Gambling, Complaint, OTC, Report, Marketing

The proposed class covers all purchasers of Evolution AB American Depositary Shares (“ADSs”) between February 14, 2019, and October 25, 2023, inclusive (the “Class Period”).

Key Points:

The proposed class covers all purchasers of Evolution AB American Depositary Shares (“ADSs”) between February 14, 2019, and October 25, 2023, inclusive (the “Class Period”).
Please contact Edelson Lechtzin LLP at 844-696-7492 or by e-mail at [email protected] to discuss your investment losses.
The Complaint alleges claims that Evolution AB and its senior officers made materially false and misleading statements regarding the company’s business, operations, and prospects.
As a result, when the facts were disclosed to the market, the price of EVVTY ADSs fell, damaging investors.

KIND INVESTOR ALERT: Edelson Lechtzin LLP Urges Nextdoor Holdings, Inc. (NYSE: KIND) f/k/a Khosla Ventures Acquisition Co. II (NASDAQ: KVSB) Shareholders to Consult Counsel About the Pending Securities Fraud Class Action

Retrieved on:

Monday, March 18, 2024

Growth, District court, COVID-19, News, LLP, Complaint, HERE, Cryptocurrency

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .

Key Points:

Please contact Edelson Lechtzin LLP at 844-696-7492 to discuss your investment losses, or by e-mail at [email protected] .
Nextdoor Holdings is a San Francisco-based company that operates a hyperlocal social networking service for neighborhoods.
It was launched in the United States in October 2011 and was available in 11 countries as of May 2023.
On this news, the price of Nextdoor common stock fell 11%, causing significant financial losses for investors.